Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis

Brain

Volumn 136, Issue 4, 2013, Pages 1067-1082

  Morsali, Damineh ^a   Bechtold, David ^b   Lee, Woojin ^a   Chauhdry, Summen ^a   Palchaudhuri, Upayan ^a   Hassoon, Paula ^b   Snell, Daniel M ^a   Malpass, Katy ^c   Piers, Thomas ^a   Pocock, Jennifer ^a   Roach, Arthur ^d   Smith, Kenneth J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d MERCK SERONO S A   (Switzerland)

Author keywords

experimental autoimmune encephalomyelitis; flecainide; microglia; neuroprotection; safinamide

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; FLECAINIDE ACETATE; GLUTATHIONE; SAFINAMIDE; SODIUM CHANNEL;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER; NERVE FIBER DEGENERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; WHITE MATTER;

EID: 84876035929     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt041     Document Type: Article

References (56)

1. Aronica E, Yankaya B, Troost D, van Vliet EA, Lopes da Silva FH, Gorter JA. Induction of neonatal sodium channel II and III alpha-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur J Neurosci 2001; 13: 1261-6.
2. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-68.
3. Bechtold DA, Hassoon PS, Smith KJ. Sodium channel blockade reduces spinal cord inflammation and neurological deficit in EAE. Society of Neuroscience Meeting Abstract 2004a; Online program 936.3.
4. Bechtold DA, Kapoor R, Smith KJ. Axonal protection mediated by flecainide therapy in experimental inflammatory demyelinating disease. J Neurol 2002; 249 (Suppl 1): 204.
5. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004b; 55: 607-16.
6. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006; 1542-51.
7. Bechtold DA, Smith KJ. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 2005; 233: 27-35.
8. Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, Smith KJ. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005; 128: 18-28.
9. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007; 62: 21-33.
10. Black JA, Liu S, Waxman SG. Sodium channel activity modulates multiple functions in microglia. Glia 2009; 57: 1072-81.
11. Black JA, Newcombe J, Waxman SG. Nav1.5 sodium channels in macrophages in multiple sclerosis lesions. Mult Scler 2012; Advance Access published on September 4, 2012, doi: 10.1177/1352458512460417.
12. Black JA, Waxman SG. Sodium channels and microglial function. Exp Neurol 2012; 234: 302-15.
13. Bortner CD, Cidlowski JA. Uncoupling cell shrinkage from apoptosis reveals that Na + influx is required for volume loss during programmed cell death. J Biol Chem 2003; 278: 39176-84.
14. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurol 2006; 67: S18-23.
15. Carrithers MD, Dib-Hajj S, Carrithers LM, Tokmoulina G, Pypaert M, Jonas EA, et al. Expression of the voltage-gated sodium channel NaV1.5 in the macrophage late endosome regulates endosomal acidification. J Immunol 2007; 178: 7822-32.
16. Carter AJ, Grauert M, Pschorn U, Bechtel WD, Bartmann-Lindholm C, Qu Y, et al. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL. Proc Natl Acad Sci USA 2000; 97: 4944-9.
17. Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005; 49: 220-9.
18. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. Voltage-dependent ion channels in T-lymphocytes. J Neuroimmunol 1985; 10: 71-95.
19. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011; 93: 1-12.
20. Ekblom J, Jossan SS, Oreland L, Walum E, Aquilonius SM. Reactive gliosis and monoamine oxidase B. J Neural Transm Suppl 1994; 41: 253-8.
21. Fernandez-Fernandez S, Almeida A, Bolanos JP. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J 2012; 443: 3-11.
22. Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb + patients. Neurol 2004; 62: 719-25.
23. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schimddaur M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89.
24. Gangemi JJ, Kern JA, Ross SD, Shockey KS, Kron IL, Tribble CG. Retrograde perfusion with a sodium channel antagonist provides ischemic spinal cord protection. Ann Thorac Surg 2000; 69: 1744-8.
25. Garthwaite G, Brown G, Batchelor AM, Goodwin DA, Garthwaite J. Mechanisms of ischaemic damage to central white matter axons: a quantitative histological analysis using rat optic nerve. Neuroscience 1999; 94: 1219-30.
26. Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G. Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity 2012; 45: 298-303.
27. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134: 1914-24.
28. Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurol 2005; 64: 236-40.
29. Hooper C, Fry VA, Sevastou IG, Pocock JM. Scavenger receptor control of chromogranin A-induced microglial stress and neurotoxic cascades. FEBS Lett 2009; 583: 3461-6.
30. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003; 53: 174-80.
31. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallelgroup trial. Lancet Neurol 2010; 9: 681-8.
32. Keelan J, Allen NJ, Antcliffe D, Pal S, Duchen MR. Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane. J Neurosci Res 2001; 66: 873-84.
33. Korotzer AR, Cotman CW. Voltage-gated currents expressed by rat microglia in culture. Glia 1992; 6: 81-8.
34. Lai ZF, Chen YZ, Nishimura Y, Nishi K. An amiloride-sensitive and voltage-dependent Na + channel in an HLA-DR-restricted human T cell clone. J Immunol 2000; 165: 83-90.
35. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 2002; 13: 1909-12.
36. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol 2003; 90: 3566-72.
37. Margaretten NC, Hincks JR, Warren RP, Coulombe RA Jr. Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. Toxicol Appl Pharmacol 1987; 87: 10-7.
38. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007; 130: 2800-15.
39. Mead EL, Mosley A, Eaton S, Dobson L, Heales SJ, Pocock JM. Microglial neurotransmitter receptors trigger superoxide production in microglia; consequences for microglial-neuronal interactions. J Neurochem 2012; 121: 287-301.
40. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurol 2007; 68: 1390-401.
41. Musgrave T, Benson C, Wong G, Browne I, Tenorio G, Rauw G, et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun 2011; 25: 1677-88.
42. Nicholson E, Randall AD. Na(v)1.5 sodium channels in a human microglial cell line. J Neuroimmunol 2009; 215: 25-30.
43. Norenberg W, Illes P, Gebicke-Haerter PJ. Sodium channel in isolated human brain macrophages (microglia). Glia 1994; 10: 165-72.
44. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinsons disease. Expert Opin Investig Drugs 2008; 17: 1115-25.
45. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995; 118: 869-78.
46. Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 1999; 288: 1151-9.
47. Schapira AH. Safinamide in the treatment of Parkinsons disease. Expert Opin Pharmacother 2010; 11: 2261-8.
48. Schmidtmayer J, Jacobsen C, Miksch G, Sievers J. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: membrane currents. Glia 1994; 12: 259-67.
49. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010; 120: 223-36.
50. Smith KJ. Newly-lesioned tissue in multiple sclerosis-a role for oxidative damage? Brain 2011; 134: 1877-1881.
51. Sontheimer H, Waxman SG. Ion channels in spinal cord astrocytes in vitro. II. Biophysical and pharmacological analysis of two Na + current types. J Neurophysiol 1992; 68: 1001-11.
52. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233: 3-13.
53. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010; 16: 406-11.
54. Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
55. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurology 2009; 8: 280-91.
56. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Valles AS, et al. The anticonvulsive drug lamotrigine blocks neuronal {alpha}4{beta}2 nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2010; 335: 401-8.